Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0RFWQY)
| ADC Name |
ADRX-0706
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ADRX-0706
Click to Show/Hide
|
|||||
| Organization |
Adcentrx Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-Nectin-4 antibody
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
AP052
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Adcentrx' proprietary linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible subjects for Phase 1a (dose escalation) must have select advanced solid tumors (e.g., UC, HNSCC, NSCLC) progressing after ≥1 prior therapy, while Phase 1b (dose expansion) focuses on UC, TNBC, or cervical cancer. Exclusions include uncontrolled CNS metastases, significant cardiovascular disease, recent anticancer therapy (<14 days/5 half-lives), and concurrent CYP3A/P-gp modifiers.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06036121 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors | ||||
| Primary Endpoint |
The study will evaluate the incidence of adverse events over an estimated 3-year period, assessing safety throughout the trial duration.
|
||||
| Other Endpoint |
Pharmacokinetic parameters (Cmax, Ctrough, AUC, t1/2, CL, Vss) of ADRX-0706 and immunogenicity via anti-drug antibodies (ADA) will be measured serially over 3 years. Efficacy endpoints include ORR, DOR, DCR, PFS, and OS, all assessed per RECIST 1.1 criteria.
|
||||